Capecitabine

Capecitabine has been studied in 6 papers since 2017: 2 trials and 1 observational study in people, 1 in animals, 1 in cells, 1 review. It is an approved medicine. The newest paper, Jan 17, 2025: “Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations”.

InterventionApproved 1998

6 papers study it5 more mention it3 findingsUpdated

PubChemChEBIMeSH

See all 11 papers on capecitabine

At a glance

The findings reach people, from one lab or study. 3 independent labs in 3 countries; 1,478 trials, 1 about aging, 458 with no results posted.

“In colon cancer, capecitabine and irinotecan was associated with higher cognitive im-pairment”
Effect of Chemotherapy and Radiotherapy on Cognitive Function in Colorectal Cancer: Evidence from National Representative Longitudinal DatabasePreprints.org2021doi:10.20944/preprints202106.0330.v1

None of its findings points the other way.

Worms or flies and humans: a single group. Cells and mice: nothing yet.
  • 3 independent labs in 3 countries
  • 1,478 trials, 1 about aging, 458 with no results posted
  • Funders: Georgia Institute of Technology and 5 more
  • Human trial2
  • Humans1
  • Model organisms1
  • Cells1

What did studies of capecitabine find?

2

Studies of capecitabine measured 2 outcomes: lifespan and CD146.

Lifespan

upin Rotifera1

1 study
  1. Capecitabine extends lifespan in Rotifera.

    “Exposures to 1 μM erythromycin, 5 μM carglumic acid, 3 μM capecitabine, and 1 μM ivermectin, extended rotifer lifespan without significant effect on reproduction.”

    Model organisms3 μM

    Repurposed FDA-approved drugs targeting genes influencing aging can extend lifespan and healthspan in rotifers

    Biogerontology

CD146

upin humans1

1 study
  1. Capecitabine is linked with higher CD146 in patients after versus before capecitabine chemotherapy.

    “sVCAM-1 and CD146 concentrations were higher after than before capecitabine chemotherapy.”

    Humansin patients after versus before capecitabine chemotherapy

    5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1

    British journal of pharmacology

More on CD146

What is capecitabine linked with?

1

Studies link capecitabine with cognitive impairment.

Cognitive impairment

upin humans1

1 study
  1. Capecitabine is linked with a higher risk of cognitive impairment in humans (colon cancer).

    “In colon cancer, capecitabine and irinotecan was associated with higher cognitive im-pairment”

    Humanscolon cancer

    Effect of Chemotherapy and Radiotherapy on Cognitive Function in Colorectal Cancer: Evidence from National Representative Longitudinal Database

    Preprints.orgPreprint

More on Cognitive impairment

Has capecitabine been tested in people?

1 of 1,478 about aging

Yes: 2 trials and 1 observational study in people have been published, and 1,478 trials are registered.

About aging

Approved

  • FDA Xeloda

    Apr 30, 1998DiscontinuedAdvanced or Metastatic Breast Cancer, Breast Cancer, Colorectal Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Cancer, Locally Advanced Rectal Cancer, Metastatic Colorectal Cancer, Pancreatic Adenocarcinoma, Pancreatic Cancer, Stage III Colon Cancer

  • EMA Xeloda

    Feb 2, 2001Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms, Advanced Gastric Cancer, Locally Advanced or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Stage III Colon Cancer

  • EMA Capecitabine Teva

    Apr 20, 2012Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms, Advanced Gastric Cancer, Locally Advanced or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Stage III Colon Cancer

  • EMA Capecitabine Accord

    Apr 20, 2012Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms, Advanced Gastric Cancer, Locally Advanced or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Colon Cancer, Stage III Colon Cancer

  • EMA Ecansya (previously Capecitabine Krka)

    Apr 20, 2012Colonic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms, Advanced Gastric Cancer, Locally Advanced or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Colon Cancer, Stage III Colon Cancer

  • EMA Capecitabine Medac

    Nov 19, 2012Colorectal Neoplasms, Advanced Gastric Cancer, Locally Advanced or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Colon Cancer, Stage III Colon Cancer

All 7

Repurposing

40 of 112

Every condition in trials

  • Adenocarcinoma of the Stomach

    Phase 4Terminated2 trials

  • HER 2 Positive Gastric Cancer

    Phase 4Status unknown2 trials

  • Locally Advanced Colorectal Cancer

    Phase 4Status unknown2 trials

  • Gastric gastroesophageal junction adenocarcinoma

    Phase 4Status unknown1 trial

  • Triple negative breast neoplasm

    Phase 3Completed37 trials

  • Biliary tract neoplasm

    Phase 3Status unknown24 trials

40 of 84

Stopped

  • NCT00216424TerminatedColorectal neoplasm

    lack of accrual

  • NCT07057089SuspendedLocally advanced rectal cancer

    Suspended due to lack of drug supply: the manufacturer ceased to provide investigational drug supply.

  • NCT00871273TerminatedAdenocarcinoma of the Stomach

    1\. Slow recruitment; 2. Change to clinical environment reducing the pool of potentially eligible patients; 3. Availability of data from another similar study

  • NCT00440622TerminatedTumor

    Due to poor accrual

  • NCT05134194TerminatedTriple negative breast neoplasm

    Sponsor R \& D Strategy Adjustment\]

  • NCT00345059TerminatedAdvanced non small cell lung cancer

    slow accrual

All 33

Who is developing capecitabine?

3 companies: Akeso, Processa Pharmaceuticals and Pfizer.

Companies
  • AkesoPhase 3gastric adenocarcinoma, gastroesophageal junction adenocarcinoma
  • Processa PharmaceuticalsPhase 2breast cancer, tnbc triple negative breast cancer
  • PfizerPhase 2breast cancer

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 1Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 03 papers in 12 months

See all 11 papers on capecitabine